Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pertti J Neuvonen

Showing results (181-190 of 192) with videos related to

Pageof 20
Sort By:
Pharmacology Research & Perspectives|January 19, 2017
Rifampicin decreases exposure to sublingual buprenorphine in healthy subjectsNora M Hagelberg, Mari Fihlman, Tuija Hemmilä, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsMikko Niemi, Janne T Backman, Lauri I Kajosaari, et al.
European Journal of Clinical Pharmacology|August 12, 2016
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interactionMari Fihlman, Tuija Hemmilä, Nora M Hagelberg, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatmentAleksi M Olkkola, Tuija Tapaninen, Aleksi Tornio, et al.
Clinical Pharmacokinetics|December 20, 2019
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug InteractionsXia Li, Sebastian Frechen, Daniel Moj, et al.
Circulation|August 17, 2011
Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protectionRaimo Tuuminen, Simo Syrjälä, Rainer Krebs, et al.
The Annals of Thoracic Surgery|April 25, 2017
Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled TrialPertti K Suominen, Juho Keski-Nisula, Tiina Ojala, et al.
Pharmacogenetics|July 1, 2004
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Mikko Niemi, Elke Schaeffeler, Thomas Lang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2017
Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions<sup> </sup>Helinä Kahma, Anne M Filppula, Mikko Neuvonen, et al.
Pharmacogenetics and Genomics|October 19, 2006
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokineticsMikko Niemi, Katja A Arnold, Janne T Backman, et al.
Pageof 20

Showing results (181-190 of 192) with videos related to

Sort By:
Pageof 20
Pharmacology Research & Perspectives|January 19, 2017
Rifampicin decreases exposure to sublingual buprenorphine in healthy subjectsNora M Hagelberg, Mari Fihlman, Tuija Hemmilä, et al.
Clinical Pharmacology and Therapeutics|June 18, 2005
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokineticsMikko Niemi, Janne T Backman, Lauri I Kajosaari, et al.
European Journal of Clinical Pharmacology|August 12, 2016
Voriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interactionMari Fihlman, Tuija Hemmilä, Nora M Hagelberg, et al.
British Journal of Clinical Pharmacology|October 23, 2023
Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatmentAleksi M Olkkola, Tuija Tapaninen, Aleksi Tornio, et al.
Clinical Pharmacokinetics|December 20, 2019
A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug InteractionsXia Li, Sebastian Frechen, Daniel Moj, et al.
Circulation|August 17, 2011
Donor simvastatin treatment abolishes rat cardiac allograft ischemia/reperfusion injury and chronic rejection through microvascular protectionRaimo Tuuminen, Simo Syrjälä, Rainer Krebs, et al.
The Annals of Thoracic Surgery|April 25, 2017
Stress-Dose Corticosteroid Versus Placebo in Neonatal Cardiac Operations: A Randomized Controlled TrialPertti K Suominen, Juho Keski-Nisula, Tiina Ojala, et al.
Pharmacogenetics|July 1, 2004
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)Mikko Niemi, Elke Schaeffeler, Thomas Lang, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|November 16, 2017
Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions<sup> </sup>Helinä Kahma, Anne M Filppula, Mikko Neuvonen, et al.
Pharmacogenetics and Genomics|October 19, 2006
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokineticsMikko Niemi, Katja A Arnold, Janne T Backman, et al.
Pageof 20